Donepezil HCL Tablets — Class III drug recall D-0784-2021
Terminated recall by Jubilant Cadista Pharmaceuticals, Inc., reported 2021-09-08, distributed nationwide. Subpotent
| Recall number | D-0784-2021 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Jubilant Cadista Pharmaceuticals, Inc., Salisbury, MD, United States |
| Recall initiated | 2021-08-20 |
| Classified | 2021-08-31 |
| Reported by FDA | 2021-09-08 |
| Terminated | 2022-04-05 |
| Distributed | Nationwide (US) |
| Quantity | 14,544 bottles |
| Reason classes | potency |
| NDC | 59746-0329-90 |
| Lot numbers | DN120006A |
| Expiration dates | 2021-12 |
Product
Donepezil HCL Tablets, USP, 5 mg, 90-count bottle, Rx only, Manufactured by: Jubilant Generics Ltd. India, Marketed by: Jubilant Cadista Pharmaceuticals Inc. Salisbury, MD 21801 NDC 59746-329-90
Reason for recall
Subpotent
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0784-2021. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.